{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/393532343"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "uture periods, the expected ability of Regulus to undertake certain activities and accomplish certain goals (including with respect to development and other activities related to RG-012 and RG-101 and with respect to the nomination of a third microRNA candidate for clinical development), the projected timeline of clinical development activities, and expectations regarding future t" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "prnewswire.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/462636299"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/393532343"] } } }
